The effects of inhibiting leukocyte migration with fucoidin in a rat peritonitis model.
OBJECTIVE
To study the effects of fucoidin on leukocyte rolling and emigration and bacterial colonization in a peritonitis sepsis model in rats.


METHODS
A controlled study in 64 male Wistar rats, anesthetized and rendered septic by cecal ligation and puncture (CLP). Immediately after CLP 32 animals received a continuous infusion of fucoidin and 32 a continuous infusion of Ringer's lactate.


RESULTS
Systemic leukocyte counts were determined every 2 h after CLP. Surviving animals were anesthetized 24 h after CLP, and intravital measurements of leukocyte rolling in venules in the cremaster muscle were performed. The animals were then killed and their organs harvested for histological and microbiological examinations. The 24-h survival was comparable in the two groups. Fucoidin-treated animals had higher leukocyte counts in the systemic circulation and lower counts in the lungs, liver, abdominal cavity, and brain than control animals. The number of bacterial colony forming units in the abdominal cavity, lungs, liver, brain and blood did not differ in the two groups. Fucoidin treatment changed the type of bacteria predominantly found in the examined organs from Escherichia coli to Pseudomonas aeruginosa.


CONCLUSIONS
In an intra-abdominal model of sepsis we found that treatment with fucoidin induces leukocytosis inhibits leukocyte rolling and reduces leukocyte emigration in the abdominal cavity, lungs, and liver. Reduction in the number of emigrating leukocytes was not associated with an increase in bacterial counts found in the examined organs.
Linnemann
G
G
Department of Anesthesiology and Intensive Care Therapy, University Hospital Jena, Germany.
Reinhart
K
K
Parade
U
U
Philipp
A
A
Pfister
W
W
Straube
E
E
Karzai
W
W
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D007262:Infusions, Intravenous; D007552:Isotonic Solutions / Q000494:pharmacology / Q000627:therapeutic use; D007958:Leukocyte Count; D007964:Leukocytosis / Q000097:blood / Q000139:chemically induced; D008297:Male; D018375:Neutrophil Activation / Q000187:drug effects; D010538:Peritonitis / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D011134:Polysaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D000077325:Ringer's Lactate; D019087:Selectins / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology / Q000401:mortality; D016019:Survival Analysis; D013997:Time Factors
D007552:Isotonic Solutions; D011134:Polysaccharides; D000077325:Ringer's Lactate; D019087:Selectins; C007789:fucoidan